$9.86
1.50% day before yesterday
Nasdaq, Sep 12, 10:02 pm CET
ISIN
US6412881053
Symbol
NPCE

NeuroPace Inc Stock price

$9.86
+0.73 8.00% 1M
-1.11 10.12% 6M
-1.33 11.89% YTD
+2.63 36.38% 1Y
+5.86 146.50% 3Y
-7.14 42.00% 5Y
-7.14 42.00% 10Y
-7.14 42.00% 20Y
Nasdaq, Closing price Fri, Sep 12 2025
-0.15 1.50%

Key metrics

Basic
Market capitalization
$326.2m
Enterprise Value
$322.7m
Net debt
positive
Cash
$62.1m
Shares outstanding
33.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
3.7 | 3.3
EV/Sales
3.6 | 3.3
EV/FCF
negative
P/B
16.8
Financial Health
Equity Ratio
8.5%
Return on Equity
-338.7%
ROCE
-22.3%
ROIC
-
Debt/Equity
3.0
Financials (TTM | estimate)
Revenue
$88.6m | $97.6m
EBITDA
$-18.0m | $-15.9m
EBIT
$-19.9m | $-22.5m
Net Income
$-25.9m | $-28.7m
Free Cash Flow
$-16.4m
Growth (TTM | estimate)
Revenue
23.3% | 22.1%
EBITDA
24.4% | 20.3%
EBIT
19.8% | -3.9%
Net Income
13.2% | -5.9%
Free Cash Flow
4.9%
Margin (TTM | estimate)
Gross
75.7%
EBITDA
-20.4% | -16.3%
EBIT
-22.4%
Net
-29.3% | -29.4%
Free Cash Flow
-18.6%
More
EPS
$-0.8
FCF per Share
$-0.5
Short interest
5.1%
Employees
209
Rev per Employee
$380.0k
Show more

Is NeuroPace Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

NeuroPace Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a NeuroPace Inc forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a NeuroPace Inc forecast:

Buy
93%
Hold
7%

Financial data from NeuroPace Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
89 89
23% 23%
100%
- Direct Costs 21 21
16% 16%
24%
67 67
26% 26%
76%
- Selling and Administrative Expenses 61 61
9% 9%
69%
- Research and Development Expense 26 26
18% 18%
29%
-18 -18
24% 24%
-20%
- Depreciation and Amortization 1.84 1.84
96% 96%
2%
EBIT (Operating Income) EBIT -20 -20
20% 20%
-22%
Net Profit -26 -26
13% 13%
-29%

In millions USD.

Don't miss a Thing! We will send you all news about NeuroPace Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

NeuroPace Inc Stock News

Neutral
Business Wire
17 days ago
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in two healthcare conferences in September. NeuroPace management will host one-on-one meetings with investors at the Wells Fargo 2025 Healthcare Conference, on Wednesday, Septe...
Neutral
Seeking Alpha
about one month ago
NeuroPace, Inc. (NASDAQ:NPCE ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Joel D. Becker - CEO, President & Director Patrick F.
Neutral
GlobeNewsWire
about one month ago
-- Reported record quarterly revenue of $23.5 million in Q2 2025-- -- Increased full-year 2025 revenue guidance to between $94 million and $98 million and gross margin guidance to between 75% and 76%-- -- Remain on track to submit NAUTILUS data to FDA for potential IGE indication expansion in the second half of 2025— --CMS maintains current MS-DRG assignment for RNS System® procedures-- MOUNTAI...
More NeuroPace Inc News

Company Profile

NeuroPace, Inc. develops, manufactures and markets implantable devices for treating epilepsy and neurological disorders. It offers implantable components which include the RNS neurostimulator as well as depth and cortical strip leads. The firm's product RNS system is designed for the treatment of medically refractory partial epilepsy includes implantable and external products. The company was founded by Robert Fischell, David Fischell, Tim Fischell, Scott Fischell, Rebecca L. Kuhn, Frank M. Fischer and Martha Morrell on November 19, 1997 and is headquartered in Mountain View, CA.

Head office United States
CEO Joel Becker
Employees 209
Founded 1997
Website www.neuropace.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today